Larry Dillaha - Harrow Health Chief Medical Officer
| HROW Stock | USD 10.27 0.05 0.48% |
Executive
Dr. Larry Dillaha, M.D. is Chief Medical Officer of the Company. Dr. Dillaha, an experienced clinical physician and a 20year veteran of the pharmaceutical industry, was previously a senior consultant to Harrow and serves on the board of directors of Melt Pharmaceuticals, a Harrowfounded business developing patented sublingual nonopioid nonIV sedation and pain drug candidates. Dr. Dillaha brings a resume of success having been the senior leader on nine FDAapproved 505 development programs across a broad range of therapeutic areas which have generated more than 1 billion in revenues. Dr. Dillaha will manage the clinical development activities of all Harrow drug development candidates throughout its portfolio of businesses. since 2019.
| Tenure | 5 years |
| Address | 102 Woodmont Boulevard, Nashville, TN, United States, 37205 |
| Phone | 615 733 4730 |
| Web | https://www.harrow.com |
Harrow Health Management Efficiency
Return On Capital Employed is likely to climb to 0 in 2024, whereas Return On Tangible Assets are likely to drop (0.17) in 2024. At this time, Harrow Health's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 146 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (2 M). Harrow Health's management efficiency ratios could be used to measure how well Harrow Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | EXECUTIVE Age | ||
| Rachael Nokes | Scpharmaceuticals | 48 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Klaus Veitinger, | Scpharmaceuticals | N/A | |
| David Krempa | Eton Pharmaceuticals | 35 | |
| Ingrid Hoos | Eton Pharmaceuticals | N/A | |
| Kevin Guthrie | Eton Pharmaceuticals | N/A | |
| Robert Andrade | Fennec Pharmaceuticals | 49 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Matthew CPA | Apyx Medical | 55 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | 0.0022 |
Harrow Health Leadership Team
Elected by the shareholders, the Harrow Health's board of directors comprises two types of representatives: Harrow Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Harrow. The board's role is to monitor Harrow Health's management team and ensure that shareholders' interests are well served. Harrow Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Harrow Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert DDS, Special Advisor | ||
| Jamie Webb, Director Relations | ||
| Larry Dillaha, Chief Medical Officer | ||
| David Moufarrge, VP Technology | ||
| John Saharek, President of ImprimisRx | ||
| Anthony Principi, Independent Director | ||
| RPh Mannebach, Head Pharmacovigilance | ||
| Andrew Boll, CFO, Secretary | ||
| Mark Baum, CEO, Director | ||
| Richard Lindstrom, Director | ||
| CFA CMA, CFO Sec | ||
| Stephen Austin, Independent Director | ||
| Andrew Livingston, Chief Officer | ||
| Larry MD, Chief Officer | ||
| Mark JD, CEO Chairman | ||
| Robert Kammer, Independent Chairman of the Board | ||
| Kim Barratt, Chief Officer | ||
| Dennis Saadeh, Chief of Formulation Strategy | ||
| John MBA, Chief Officer | ||
| Dennis PharmD, Chief Strategy | ||
| CMA CFA, CFO Secretary |
Harrow Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Harrow Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | 0.0022 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 470.57 M | ||||
| Shares Outstanding | 35.36 M | ||||
| Shares Owned By Insiders | 14.58 % | ||||
| Shares Owned By Institutions | 66.68 % | ||||
| Number Of Shares Shorted | 6.12 M | ||||
| Price To Earning | 24.45 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Harrow Stock please use our How to Invest in Harrow Health guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Harrow Stock analysis
When running Harrow Health's price analysis, check to measure Harrow Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harrow Health is operating at the current time. Most of Harrow Health's value examination focuses on studying past and present price action to predict the probability of Harrow Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harrow Health's price. Additionally, you may evaluate how the addition of Harrow Health to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Harrow Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Earnings Share (0.75) | Revenue Per Share 3.992 | Quarterly Revenue Growth 0.788 | Return On Assets 0.0022 |
The market value of Harrow Health is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.